Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Trading opportunity emerges with share price fall

Polynovo
3:27pm
February 24, 2025
PNV posted its 1H25 result which was in line with expectations. However, the share price fell sharply (down 8%) which we found surprising and believe has created a buying opportunity. Our forecast growth of 29% for FY25 appears achievable driven by regional expansion and additional indications. We have made no changes to forecasts or TP. Add recommendation maintained.

It’s still tough out there

Reece
3:27pm
February 24, 2025
REH’s 1H25 result was slightly weaker than expected with the housing outlook in both ANZ and the US remaining soft. Key positive: Balance sheet remains healthy with ND/EBITDA (ex-leases) at 0.8x, leaving capacity for ongoing growth investments that will benefit the business over the long term. Key negatives: Volumes and margins were lower in both ANZ and the US; Increased competition has led to market share loss in the US; Cost inflation remains a headwind. We decrease FY25-27F EBITDA by between 2-3%. Our target price falls to $18.70 (from $19.95) and with a 12-month forecast TSR of -1%, we upgrade our rating to Hold (from Reduce). While we continue to see REH as a good business with a strong culture and long track record of growth, the outlook for housing in the near-term remains uncertain despite a likely peak in central bank interest rates in both Australia and the US. REH will also need to respond to aggressive competition in the US, which also adds to the uncertainty on the earnings outlook.

All weather steel cycle performance, with yield

Stanmore Resources
3:27pm
February 24, 2025
Key CY24 financials beat our expectations driven by better realisations/ revenues. The US 6.7c dividend was a positive surprise, helped by a robust balance sheet and a material step down in 2025 capex as internal investment completes. CY25 guidance was materially better than our conservative expectations. SMR trades at ~0.65x P/NPV reflecting depressed investor interest and opacity in the global steel outlook. With a robust balance sheet, and dividends through the cycle, we think SMR offers a compelling option over steel market upside in time for patient investors.

Will organisational reshuffles

Ramsay Health Care
3:27pm
February 24, 2025
Since taking over the reins last Dec, CEO Natalie Davis has started running a ruler over operations, flagging senior leadership changes, updating the operational structure and writing down goodwill related to Elysium mental health business in the UK. Preliminary 1HFY25 results have also been released, which sees underlying operating income decline 1-3% on pcp, and management no longer expecting NPAT growth in FY25. At this early stage, it is difficult to assess if adjustments in operational strategy will have the desired impact, so we continue to remain cautious. We adjust FY25-27 earnings lower, mainly in out years, with our price target decreasing to A$37.74. Hold. CFO Martyn Roberts and Australia CEO Carmel Monaghan will be exiting stage left, with Mr Roberts resigning to “pursue other opportunities” and Ms Monaghan retiring mid-2025. Both will remain with the company during a transition phase. An updated operational structure, which aims to “strengthen the group’s focus on its core Australian hospital business, while building the capabilities necessary to drive transformation and shareholder value”, is slated to be implemented by mid-25 with key changes including: RHC will take a A$291m post-tax goodwill impairment of Elysium, driven by continued occupancy challenges in mental health rehabilitation and neurological services, as well as a slower than planned ramp up in occupancy at new site, partially offset by the increase in valuation for UK Hospitals driven by an improved tariff outlook in 2004/05 and public/private partnership momentum. In an attempt to improve Elysium’s performance, a COO commended in Jan-25, targeting “operational rigour” with a “focus on financial outcomes”. In addition, consultants have been hired to “identify initiatives to improve profitability”. A A$64.5m tax liability provision release for Ramsay Santé will also be taken, as the time period to hold the provision has lapsed.

NEU adds another two zombie designations

Neuren Pharmaceuticals
3:27pm
February 24, 2025
NEU has announced the granting of FDA’s Rare Pediatric Disease Designation (RPD) for both Pitt Hopkins (PH) and Angelman Syndrome (AS), both neurological disorders which emerge in early childhood and currently have no approved treatments. These designations allow companies to apply for various incentives, including the highly-prized Priority Review Voucher (PRV) which awards RPD participants a voucher which can be used to accelerate the FDA’s review process, or can opt to on-sell to another drug developer to use. However, there remains uncertainty under current legislation where the PRV program was active up until September 2024 but has not since been reauthorised. The sunsetting of incentives currently only allows the awarding of the vouchers for approved designations up until late 2026, but seemingly not the qualifying tickets to entry which it continues to award. Given the time it takes to run Ph3 pivotal trials along with the NDA submission process, the designations are effectively zombie designations with no material benefit unless US congress reauthorise the program. A bill introduced in December 2024 (with bipartisan support) which would have extended the sunset date for another 4+ years ran into political challenges and ultimately stripped back many provisions which included the PRV extension. We note that congress has since passed several of the bills originally stripped out of the continuing resolutions, which gives some degree of hope for the program in the near-term. However, from our searches we cannot find any current commentary from the FDA or heard of this program being on the ticket for discussion at the congressional level at this stage.

1H25 earnings: From holding the ball to tightening the reins

Tabcorp Holdings
3:27pm
February 24, 2025
TAH’s 1H25 result was its most encouraging update for some time prompting a positive share price reaction on the day. The appointment of Gill McLachlan as CEO is a key catalyst for driving change, as reflected in his first interim result. Despite softer turnover, total domestic wagering revenue (pre-VRI interest) rose 1%, supported by strong cash performance and resilient digital yields. Encouragingly, FY25 OpEx savings guidance increased from $20m to $30m (MorgansF: $693m) while CapEx and D&A guidance were also revised downwards. Following the result, we have raised our earnings forecasts by 3.2% in FY25 and 1.4% in FY26. Our key takeaway from the investor call is a notable shift in sentiment compared to the previous year. While near-term wagering conditions may appear choppy, we see long-term potential, supported by a series of specialised hires aimed at maximising value from TAH's existing asset base. We upgrade TAH to an Add recommendation and increase our price target to $0.75.

Cooler Runnings

Lindsay Australia
3:27pm
February 23, 2025
LAU’s 1H25 result was much weaker than expected as softer trading conditions and increased competition impacted LAU’s transport segment. Group EBITDA (pre AASB16) of A$47.3m was down -9.2% yoy, -7% lower than MorgF $50.8m. Underlying NPAT also fell -20% yoy to $15.8m also short of MorgF/ Consensus. Management commentary reflects expectations for operating conditions to remain challenging into 2H25. Given this near-term outlook and uncertainty surrounding the recovery in broader conditions we reduce FY25-27F EBITDA by -15%. We move to a Hold rating with a revised target of $0.80ps (from $1.15ps).

1H25 earnings: Upside beyond jackpot cycles

Jumbo Interactive
3:27pm
February 23, 2025
JIN delivered a resilient result despite a weaker jackpotting period in the first half. Looking ahead, JIN will be comping its strongest second half to date, though margins should benefit from effective cost management and incremental upside from Daily Winners. We remain comfortable sitting below consensus for FY26, given uncertainties around draws and recovery in Managed Services. Despite this, we see limited downside (<10x FY25-26F EV/EBITDA), supported by a strong net cash position. We see upside to guided Managed Services margins, driven by contract mix and FX benefits. We maintain our Add recommendation, with our PT reduced to $13.60 (previously $14.60).

Lets taco’bout those comps

Guzman y Gomez
3:27pm
February 23, 2025
Whilst GYG’s 1H25 result didn’t deliver a much anticipated beat and consensus earnings upgrade, it was nonetheless a strong half of execution and growth. Importantly, comp sales growth continues to accelerate into the 2H25 and GYG now expects to exceed its prospectus forecasts (consensus was already above). Following share price weakness, we upgrade to ADD.

Better than feared

Inghams
3:27pm
February 23, 2025
As we expected, ING reported a weak 1H25 result given it was comping a record pcp. However, importantly the result was in line with our forecast and was better than feared. The 1H25 was impacted by weakness in out-of-home channels due to cost-of-living pressures. FY25 guidance was maintained which implies that solid earnings growth will resume in the 2H25. However, uncertainty remains over FY26 earnings given the WOW contract hasn’t been fully replaced, albeit ING has made solid progress. Given FY26 is likely a transition year, the stock is lacking share price catalysts and with less than 10% upside to our price target, we move to a Hold rating. We expect that ING’s attractive fully franked dividend yield will provide share price support.

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more